Lumos Pharma (LUMO) Competitors

Allarity Therapeutics (NASDAQ:ALLR) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Which has preferable valuation and earnings, ALLR or LUMO?

Allarity Therapeutics has higher earnings, but lower revenue than Lumos Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	N/A	N/A	-$11.90M	N/A	N/A
Lumos Pharma	$2.05M	10.38	-$34.03M	-$4.19	-0.63

Do analysts rate ALLR or LUMO?

Lumos Pharma has a consensus target price of $18.00, suggesting a potential upside of 587.02%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Lumos Pharma is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Lumos Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of ALLR or LUMO?

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Comparatively, 23.7% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more volatility and risk, ALLR or LUMO?

Allarity Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Does the media refer more to ALLR or LUMO?

In the previous week, Allarity Therapeutics had 3 more articles in the media than Lumos Pharma. MarketBeat recorded 4 mentions for Allarity Therapeutics and 1 mentions for Lumos Pharma. Lumos Pharma's average media sentiment score of 0.18 beat Allarity Therapeutics' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lumos Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor ALLR or LUMO?

Lumos Pharma received 33 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 77.27% of users gave Lumos Pharma an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.

Company	Underperform	Outperform
Allarity Therapeutics	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%
Lumos Pharma	Outperform Votes 34 77.27%	Underperform Votes 10 22.73%

Is ALLR or LUMO more profitable?

Allarity Therapeutics has a net margin of 0.00% compared to Allarity Therapeutics' net margin of -1,659.39%. Lumos Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	N/A	-91.78%
Lumos Pharma	-1,659.39%	-85.63%	-65.30%

Summary

Lumos Pharma beats Allarity Therapeutics on 9 of the 14 factors compared between the two stocks.